量子生物药剂利用新的PET追踪器实时监测马萨诸塞州总医院的记忆破灭情况,推进MS治疗研究。 Quantum BioPharma advances MS treatment research using a new PET tracer to monitor remyelination in real time with Massachusetts General Hospital.

量子生物药厂(QNTM)正在推进其卢西德-MS多发性硬化症方案,使用新型PET追踪器实时跟踪马萨诸塞州综合医院的失明情况。 Quantum BioPharma (QNTM) is advancing its Lucid-MS program for multiple sclerosis using a novel PET tracer to track remyelination in real time with Massachusetts General Hospital. 该公司经营三个综合单位:神经科学研究、通过Celly Nu将未加工的饮料商业化和通过上流双重上市进入数字市场,上流是一个有利于近实时定居点的平台。 The company operates three integrated units: neuroscience research, commercialization of the unbuzzd™ beverage via Celly Nu, and digital market access through a dual listing on Upstream, a platform enabling near-instant settlements. 这一“数字资产负债表框架”旨在加强透明度、效率和投资者参与,在预计到2030年全球生物技术市场3万亿美元的情况下,将量子作为下一代生物技术公司的模式。 This “digital balance-sheet framework” aims to enhance transparency, efficiency, and investor engagement, positioning Quantum as a model for next-generation biotech firms amid a projected $3 trillion global biotech market by 2030.